Metformin inhibits nuclear translocation of NF-κB components and their transactivation at target promoters, thereby suppressing SASP factor expression—mechanistically explaining its anti-aging and anti-tumor effects in diabetic models and patients (Guo et al., 2024). This evidence concerns the gene NFKB1 and neoplasm.